Nobel laureate Stiglitz leads expert discussions on restoring country as rice bowl of Asia
The United Nations Economic and Social Commission for Asia and the Pacific (ESCAP) and the Government of the Union of Myanmar today held a wide-ranging dialogue aimed at boosting the countrys agricultural sector and to help it reclaim its status as the rice bowl of Asia.
At the invitation of ESCAP, Nobel Prize-winning economist Prof. Joseph Stiglitz and other eminent experts discussed strategies for Myanmar to cut poverty in light of Asias regional and subregional experiences.
It is my hope these ideas and analysis will open a new space for policy discussion and a further deepening of our development partnership, UN Under-Secretary-General and ESCAP Executive Secretary Noeleen Heyzer said at the event held in Myanmars capital, Naypyitaw.
These development objectives can only be achieved through the successful engagement of local experts and people who know what is happening on the ground. This development partnership, requested by the Government of Myanmar, provides a unique platform for eminent international scholars and local researchers to exchange experiences and ideas with government agencies and civil society, Dr. Heyzer added.
This is the second in a series of events launched by Dr. Heyzer during her visit in July to Myanmar, and was organized by ESCAP with the countrys Ministry of Agriculture and Irrigation and Ministry of National Planning and Economic Development.
In his presentation, Towards a more productive agrarian economy for Myanmar, Professor Stiglitz noted that Myanmar was well-positioned to learn from other countries in the region that have developed on the back of gains in agriculture. There are large opportunities for improvement. Myanmar should take a comprehensive approach, he said.
He urged the Government of Myanmar to: promote access to appropriate agricultural financing; take measures to boost access to seeds and fertilizers; dramatically boost spending on health and education; and create well-paid jobs in construction of rural infrastructure in order to stimulate development and raise incomes and spending.
Professor Stiglitz also noted that well-functioning institutions were critical to success, and that Myanmar could learn from the mistakes made by other resource-rich countries. Revenues from oil and gas can open up a new era, if used well. If not, then valuable opportunities will be squandered, he said.
Economics and politics can not be separated, Professor Stiglitz added. For Myanmar to take a role on the world stage and to achieve true stability and security there must be widespread participation and inclusive processes. This is the only way forward for Myanmar.
Maj. Gen. U Htay Oo, Minister of Agriculture and Irrigation of Myanmar, noted that climate change has had significant effects on the countrys agriculture and livelihood, particularly in the dry zone. To mitigate such pressure we are implementing short-term and longer term measures, such as promoting access to irrigation water to increase productivity, and developing resource-based as well as knowledge-based sustainable agriculture and livelihoods built on existing infrastructures, he said.
We are adopting a holistic approach informed by the human development perspective to address the needs of the most vulnerable, he added. We cannot afford to be complacent thus the tasks for agriculture and rural development must be implemented through mass movement.
The Minister also welcomed and supported the continued close cooperation and collaboration of ESCAP in the development partnership series. I look forward to the joint activities to come in 2010, in particular the regional development programme for sustainable agriculture towards inclusive rural economy development, he said.
Col. Thurin Zaw, Deputy Minister of National Planning and Economic Development, delivered a presentation on Myanmars National development plans and the implementation of the Millennium Development Goals (MDGs).
The meeting was organized into two segments: The morning roundtable was devoted to expert discussions and included presentations on Recent socio-economic development, by Daw Khin Ma Ma Swe of the Ministry of National Planning and Economic Development, and on Approaches for agriculture and rural development, by Daw Dolly Kyaw of the Ministry of Agriculture and Irrigation.
There were also presentations on Establishing the virtuous cycle of food security, sustainable agriculture and rural economy development, by U Tin Htut Oo and U Tin Maung Shwe of the Academy of Agriculture, Forestry, Livestock and Fisheries Sciences, and on Enhancing Myanmars rural economy, by Ikuko Okamoto of the Institute of Developing Economies-JETRO.
The afternoon high-level development forum covered, Economic policies for growth and poverty reduction: lessons from the region and beyond.
On 21 December in Singapore, Professor Stiglitz and Dr Heyzer will hold a press conference about the forum at the Singapore Foreign Correspondents Association. The press conference will take place at the Singapore Management University, Administration Building, from 9am-10am.
Wednesday, December 16, 2009
Published in "Bone" Journal, Scientific Researches Confirm Peptan(TM) Hydrolyzed Collagen Benefits on Bone Health
Studies Conducted at INRA-AgroParisTech Laboratory Under Pr. Daniel Tomé Supervision and Published* in November 2009, in the Official Journal of the International Bone and Mineral Society "Bone", Reveal new Benefits for Peptan(TM) in Osteoporosis Prevention In response to customer concerns regarding long-term bone health, Rousselot has carried out, for several years now, many studies to demonstrate that an oral intake of Peptan(TM) may have a positive impact on osteoporosis.
Bone is a living dynamic metabolic system that relies on a maintained balance between bone formation and bone resorption. Cells called osteoblasts make bone while cells called osteoclasts resorb it. An imbalance
may lead to osteoporosis, a condition where the density and quality of bone is reduced.
Researchers conducted in vitro studies, and highlighted that Peptan(TM) in bone cell culture induced a better differentiation of osteoblasts. Those positive results have then been confirmed in vivo on ovariectomized mice, used to simulate a postmenopausal osteoporosis, which leads to a lower bone mineral density (BMD).
Animals were divided into three groups: a control group (non ovariectomized), a group of ovariectomized mice, both fed with a normal diet and a group of ovariectomized mice that received a diet containing Peptan(TM). After 12 weeks, the BMD of the group fed with Peptan(TM) is not significantly different from the BMD of control group. On the contrary the BMD of ovariectomized mice not fed with Peptan(TM) is lower.
Confirmation of Peptan(TM) benefits on bone health has been obtained by the measures of Carboxy Terminal Telopeptide (CTX), a usual marker of bone resorption. CTX is significantly lower in mice fed with
PeptanTM indicating that bone resorption is reduced.
Researchers conclude that Peptan(TM) may restore bone density in simulated post-menopausal osteoporosis by stimulating osteoblast growth and differentiation. This demonstrates the interest of Peptan(TM) as a bioactive ingredient to help preventing bone loss during aging.
*Hydrolyzed collagen improves bone metabolism and biomechanical parameters in ovariectomized mice: an in vitro and in vivo study. Guillerminet et al. Bone 2009.
Rousselot, http://www.rousselot.com
Part of VION N.V. (N.L.), Rousselot(R) is the worldwide leader in gelatine and hydrolyzed collagen. VION N.V. is an internationally operating food group that produces high-quality foods and ingredients for
humans and animals (Turnover: EUR 9.6 billion - 31,000 employees worldwide)
Bone is a living dynamic metabolic system that relies on a maintained balance between bone formation and bone resorption. Cells called osteoblasts make bone while cells called osteoclasts resorb it. An imbalance
may lead to osteoporosis, a condition where the density and quality of bone is reduced.
Researchers conducted in vitro studies, and highlighted that Peptan(TM) in bone cell culture induced a better differentiation of osteoblasts. Those positive results have then been confirmed in vivo on ovariectomized mice, used to simulate a postmenopausal osteoporosis, which leads to a lower bone mineral density (BMD).
Animals were divided into three groups: a control group (non ovariectomized), a group of ovariectomized mice, both fed with a normal diet and a group of ovariectomized mice that received a diet containing Peptan(TM). After 12 weeks, the BMD of the group fed with Peptan(TM) is not significantly different from the BMD of control group. On the contrary the BMD of ovariectomized mice not fed with Peptan(TM) is lower.
Confirmation of Peptan(TM) benefits on bone health has been obtained by the measures of Carboxy Terminal Telopeptide (CTX), a usual marker of bone resorption. CTX is significantly lower in mice fed with
PeptanTM indicating that bone resorption is reduced.
Researchers conclude that Peptan(TM) may restore bone density in simulated post-menopausal osteoporosis by stimulating osteoblast growth and differentiation. This demonstrates the interest of Peptan(TM) as a bioactive ingredient to help preventing bone loss during aging.
*Hydrolyzed collagen improves bone metabolism and biomechanical parameters in ovariectomized mice: an in vitro and in vivo study. Guillerminet et al. Bone 2009.
Rousselot, http://www.rousselot.com
Part of VION N.V. (N.L.), Rousselot(R) is the worldwide leader in gelatine and hydrolyzed collagen. VION N.V. is an internationally operating food group that produces high-quality foods and ingredients for
humans and animals (Turnover: EUR 9.6 billion - 31,000 employees worldwide)
TeliaSonera and Huawei Launch World’s Fastest Commercial Mobile Broadband Network with Huawei’s 4G/LTE Solutions
TeliaSonera and Huawei Launch World’s Fastest Commercial Mobile Broadband Network with Huawei’s 4G/LTE Solutions
Huawei, a leader in providing next-generation telecommunications network solutions for operators around the world, and TeliaSonera, the largest telecoms operator in Scandinavia and the Baltic countries, today jointly announced the deployment of the world’s first LTE commercial network in Oslo, Norway. These 4G services offer maximum speeds of up to 100 Mb/s and are approximately 10 times faster than existing 3G networks.
TeliaSonera’s customers will be the first in the world to enjoy simultaneous mobile broadband services such as high definition (HD) video conferencing in mobile environments and a variety of HD video programs via multiple terminal devices; applications that cannot be realized in current 3G networks.
Mr. Kenneth Karlberg, President and Head of Mobility Services TeliaSonera, said: “We are very proud to be the first operator in the world to offer our customers 4G services. Thanks to the successful cooperation with Huawei, we can offer 4G to our customers in Oslo earlier than originally planned.”
As a leading provider of end-to-end 4G/LTE solutions, Huawei delivered both network infrastructures and services to TeliaSonera, such as access network, core network, operation support system, and network planning and optimization. Its field proven fourth-generation base stations and SAE (System Architecture Evolution) solution ensure the stability of the network and enable fast deployment.
Yu Chengdong, President of Huawei Europe, said: “In partnership with TeliaSonera, Huawei began this journey eleven months ago to introduce the world’s most advanced mobile broadband technology to the residents of Oslo. This milestone, which was achieved in a short period of time, reflects Huawei’s unwavering commitment towards accelerating the commercialization of LTE/SAE solutions. Operators such as TeliaSonera, are now able to to fully realize economic benefits from the many new applications that can only be made possible with ultra broadband services.”
To date, Huawei has constructed over 25 LTE commercial and trial networks and has made more than 3,300 LTE/SAE contributions to 3GPP (3rd Generation Partnership Project).
About Huawei
Huawei is a leader in providing next generation telecommunications networks, and now serves 36 of the world’s top 50 operators, along with over one billion users worldwide. The company is committed to providing innovative and customized products, services and solutions to create long-term value and growth potential for its customers.
Huawei, a leader in providing next-generation telecommunications network solutions for operators around the world, and TeliaSonera, the largest telecoms operator in Scandinavia and the Baltic countries, today jointly announced the deployment of the world’s first LTE commercial network in Oslo, Norway. These 4G services offer maximum speeds of up to 100 Mb/s and are approximately 10 times faster than existing 3G networks.
TeliaSonera’s customers will be the first in the world to enjoy simultaneous mobile broadband services such as high definition (HD) video conferencing in mobile environments and a variety of HD video programs via multiple terminal devices; applications that cannot be realized in current 3G networks.
Mr. Kenneth Karlberg, President and Head of Mobility Services TeliaSonera, said: “We are very proud to be the first operator in the world to offer our customers 4G services. Thanks to the successful cooperation with Huawei, we can offer 4G to our customers in Oslo earlier than originally planned.”
As a leading provider of end-to-end 4G/LTE solutions, Huawei delivered both network infrastructures and services to TeliaSonera, such as access network, core network, operation support system, and network planning and optimization. Its field proven fourth-generation base stations and SAE (System Architecture Evolution) solution ensure the stability of the network and enable fast deployment.
Yu Chengdong, President of Huawei Europe, said: “In partnership with TeliaSonera, Huawei began this journey eleven months ago to introduce the world’s most advanced mobile broadband technology to the residents of Oslo. This milestone, which was achieved in a short period of time, reflects Huawei’s unwavering commitment towards accelerating the commercialization of LTE/SAE solutions. Operators such as TeliaSonera, are now able to to fully realize economic benefits from the many new applications that can only be made possible with ultra broadband services.”
To date, Huawei has constructed over 25 LTE commercial and trial networks and has made more than 3,300 LTE/SAE contributions to 3GPP (3rd Generation Partnership Project).
About Huawei
Huawei is a leader in providing next generation telecommunications networks, and now serves 36 of the world’s top 50 operators, along with over one billion users worldwide. The company is committed to providing innovative and customized products, services and solutions to create long-term value and growth potential for its customers.
Tuesday, December 15, 2009
Competitive Technologies Announces European Regional Distributor
Competitive Technologies, Inc. (NYSE Amex:CTT) announced today that its Geneva, Switzerland-based distributor, Life Episteme SARL, has established a joint venture, Life Episteme Italia srl, with Florence, Italy-based Hospital Consulting SpA, to distribute CTT's pain therapy medical device, Calmare(R) Therapy Treatment throughout Italy.
"Life Episteme is eager to embark on this joint venture with Hospital Consulting,
which is well known in the Italian healthcare sector," said Life Episteme co-founder
Dr. Domenico Pecorini. "This agreement with Hospital Consulting finalizes the first
of several regional joint ventures we have in negotiation as part of our strategy
for distributing CTT's innovative Calmare(R) Therapy Treatment in the global
marketplace."
"Hospital Consulting has the infrastructure in place, and has extensive experience working with healthcare providers throughout Italy," said John B. Nano, CTT's Chairman, President and CEO. "We're pleased to have them join the distribution team for our Calmare(R) Therapy Treatment, which has already successfully treated more than 3,000 patients in Europe and the U.S.
"Pain treatment is moving to the forefront of medical care, globally. In Italy,
Europe's largest university, La Sapienza of Rome, will prominently feature our
Calmare(R) Therapy Treatment at its newly-established medical school dedicated to
the treatment of pain. Hospital Consulting's recognition of important trends in
healthcare confirms our belief that the ability to help patients with debilitating
pain by using our non-invasive pain therapy treatment device is an attractive
alternative for physicians who may be reluctant to prescribe powerful, addictive
narcotics that have been linked to harmful, potentially fatal, adverse side effects.
"Recently, the University of Chicago Medical Center announced that, '... a growing body of evidence is showing that opiate-based painkillers can stimulate the growth and spread of cancer cells.' This makes the rapid introduction of our Calmare(R) Therapy Treatment into the global healthcare marketplace even more compelling. In
fact, similar to the Hippocratic Oath, a fundamental principle taught to all medical
students is 'Primum Non Nocere,' meaning, 'First, do no harm.'"
The Calmare(R) Therapy Treatment is a prime example of CTT's strategy to connect
clinical science to patient care. Developed in Italy by CTT's client, Professor
Giuseppe Marineo, the device was brought to CTT through the efforts of the Zangani
Investor Community(TM) and with the cooperation of Mr. Guiseppe Belcastro, Legal
Counsel for Professor Marineo. The device, with a biophysical rather than a
biochemical approach, uses a multi-processor able to simultaneously treat multiple
pain areas by applying surface electrodes to the skin. CTT has exclusive worldwide
rights to the Calmare(R) Therapy Treatment which has U.S. FDA acceptance and Medical
Device CE Mark certification from the E.U. allowing sales throughout the U.S.,
Europe and several other countries. CTT partner, GEOMC Co., Ltd. of Korea, is
producing the device commercially for worldwide distribution. Several distribution
agreements, including the one with Life Episteme, are in place covering 45 countries
around the world, accounting for nearly 55% of the world's population. For more information on the device, visit www.CalmareTT.com.
About Hospital Consulting, SpA
Based in Florence, Italy, Hospital Consulting SpA provides advisory, management and organizational services to the healthcare and environment sectors. Hospital
Consulting provides hospitals and other health care providers throughout Italy with
valuable training, facility design and development as well as innovative risk
assessment and information technology solutions. For more information, see Hospital
Consulting's website: www.hospital-consulting.it.
About Life Episteme SARL
The privately held Life Episteme SARL based in Geneva, Switzerland, is a medical
device distribution company. The experience of the co-founders, Dr. Domenico
Pecorini, Vincenzo de Bustis Figarola, and Paolo Pepe, has provided the group with
strong relationships in government, business, and technology spheres in various
countries around the world. Visit Dr. Pecorini's website: www.scienceparkrome.eu.
About Life Episteme Italia, srl
This newly formed Joint Venture will benefit from the know-how and contacts of both Hospital Consulting (HC) and Life Episteme SARL group (LEG). The success of the
operation will be pursued sharing competencies and dedicating high-profile
resources. LEG will bring strong relationships, financial services and
internationalization to the partnership. HC will provide decades of presence,
success and experience in the market. The President of Life Episteme Italia (LEI)
will be Dott.ssa Marisa Giampaoli, Managing Director of Hospital Consulting group,
who is well respected at the highest levels of the Italian public and private health
sector. Umberto Marangoni, the Country General Manager for Hospital Consulting, will
serve as LEI's Managing Director. Before becoming the Country General Manager, he
worked many years in the same positions in Italy and abroad, for Ohmeda and Draeger
Medical, the world leaders in Anesthesia and Critical Care. LEI and the Italian
activities will become fully operational beginning January 1, 2010.
About Zangani Investor Community(TM)
The Zangani Investor Community(TM) was created to facilitate scientific and
commercial relationships between American, European and Chinese entities. Visit
Zangani's website: www.zangani.com.
About Professor Guiseppe Marineo
Professor Guiseppe Marineo is a researcher and bioengineer, who advanced theories to reformulate the concept of disease and the corresponding treatment from a
biophysical rather than a biochemical point of view. He is the founder of Delta R&D,
a bioengineering research center with a unique history. Visit Delta R&D's website:
www.deltard.com/eng.
About Competitive Technologies, Inc.
Competitive Technologies, established in 1968, provides distribution, patent and
technology transfer, sales and licensing services focused on the needs of its
customers and matching those requirements with commercially viable product or
technology solutions. CTT is a global leader in identifying, developing and
commercializing innovative products and technologies in life, electronic, nano, and
physical sciences developed by universities, companies and inventors. CTT maximizes
the value of intellectual assets for the benefit of its customers, clients and
shareholders. Visit CTT's website: www.competitivetech.net.
Statements made about our future expectations are forward-looking statements and
subject to risks and uncertainties as described in our most recent Annual Report on
Form 10-K for the year ended July 31, 2009, filed with the SEC on October 27, 2009,
and other filings with the SEC, and are subject to change at any time. Our actual
results could differ materially from these forward-looking statements. We undertake
no obligation to update publicly any forward-looking statement.
"Life Episteme is eager to embark on this joint venture with Hospital Consulting,
which is well known in the Italian healthcare sector," said Life Episteme co-founder
Dr. Domenico Pecorini. "This agreement with Hospital Consulting finalizes the first
of several regional joint ventures we have in negotiation as part of our strategy
for distributing CTT's innovative Calmare(R) Therapy Treatment in the global
marketplace."
"Hospital Consulting has the infrastructure in place, and has extensive experience working with healthcare providers throughout Italy," said John B. Nano, CTT's Chairman, President and CEO. "We're pleased to have them join the distribution team for our Calmare(R) Therapy Treatment, which has already successfully treated more than 3,000 patients in Europe and the U.S.
"Pain treatment is moving to the forefront of medical care, globally. In Italy,
Europe's largest university, La Sapienza of Rome, will prominently feature our
Calmare(R) Therapy Treatment at its newly-established medical school dedicated to
the treatment of pain. Hospital Consulting's recognition of important trends in
healthcare confirms our belief that the ability to help patients with debilitating
pain by using our non-invasive pain therapy treatment device is an attractive
alternative for physicians who may be reluctant to prescribe powerful, addictive
narcotics that have been linked to harmful, potentially fatal, adverse side effects.
"Recently, the University of Chicago Medical Center announced that, '... a growing body of evidence is showing that opiate-based painkillers can stimulate the growth and spread of cancer cells.' This makes the rapid introduction of our Calmare(R) Therapy Treatment into the global healthcare marketplace even more compelling. In
fact, similar to the Hippocratic Oath, a fundamental principle taught to all medical
students is 'Primum Non Nocere,' meaning, 'First, do no harm.'"
The Calmare(R) Therapy Treatment is a prime example of CTT's strategy to connect
clinical science to patient care. Developed in Italy by CTT's client, Professor
Giuseppe Marineo, the device was brought to CTT through the efforts of the Zangani
Investor Community(TM) and with the cooperation of Mr. Guiseppe Belcastro, Legal
Counsel for Professor Marineo. The device, with a biophysical rather than a
biochemical approach, uses a multi-processor able to simultaneously treat multiple
pain areas by applying surface electrodes to the skin. CTT has exclusive worldwide
rights to the Calmare(R) Therapy Treatment which has U.S. FDA acceptance and Medical
Device CE Mark certification from the E.U. allowing sales throughout the U.S.,
Europe and several other countries. CTT partner, GEOMC Co., Ltd. of Korea, is
producing the device commercially for worldwide distribution. Several distribution
agreements, including the one with Life Episteme, are in place covering 45 countries
around the world, accounting for nearly 55% of the world's population. For more information on the device, visit www.CalmareTT.com.
About Hospital Consulting, SpA
Based in Florence, Italy, Hospital Consulting SpA provides advisory, management and organizational services to the healthcare and environment sectors. Hospital
Consulting provides hospitals and other health care providers throughout Italy with
valuable training, facility design and development as well as innovative risk
assessment and information technology solutions. For more information, see Hospital
Consulting's website: www.hospital-consulting.it.
About Life Episteme SARL
The privately held Life Episteme SARL based in Geneva, Switzerland, is a medical
device distribution company. The experience of the co-founders, Dr. Domenico
Pecorini, Vincenzo de Bustis Figarola, and Paolo Pepe, has provided the group with
strong relationships in government, business, and technology spheres in various
countries around the world. Visit Dr. Pecorini's website: www.scienceparkrome.eu.
About Life Episteme Italia, srl
This newly formed Joint Venture will benefit from the know-how and contacts of both Hospital Consulting (HC) and Life Episteme SARL group (LEG). The success of the
operation will be pursued sharing competencies and dedicating high-profile
resources. LEG will bring strong relationships, financial services and
internationalization to the partnership. HC will provide decades of presence,
success and experience in the market. The President of Life Episteme Italia (LEI)
will be Dott.ssa Marisa Giampaoli, Managing Director of Hospital Consulting group,
who is well respected at the highest levels of the Italian public and private health
sector. Umberto Marangoni, the Country General Manager for Hospital Consulting, will
serve as LEI's Managing Director. Before becoming the Country General Manager, he
worked many years in the same positions in Italy and abroad, for Ohmeda and Draeger
Medical, the world leaders in Anesthesia and Critical Care. LEI and the Italian
activities will become fully operational beginning January 1, 2010.
About Zangani Investor Community(TM)
The Zangani Investor Community(TM) was created to facilitate scientific and
commercial relationships between American, European and Chinese entities. Visit
Zangani's website: www.zangani.com.
About Professor Guiseppe Marineo
Professor Guiseppe Marineo is a researcher and bioengineer, who advanced theories to reformulate the concept of disease and the corresponding treatment from a
biophysical rather than a biochemical point of view. He is the founder of Delta R&D,
a bioengineering research center with a unique history. Visit Delta R&D's website:
www.deltard.com/eng.
About Competitive Technologies, Inc.
Competitive Technologies, established in 1968, provides distribution, patent and
technology transfer, sales and licensing services focused on the needs of its
customers and matching those requirements with commercially viable product or
technology solutions. CTT is a global leader in identifying, developing and
commercializing innovative products and technologies in life, electronic, nano, and
physical sciences developed by universities, companies and inventors. CTT maximizes
the value of intellectual assets for the benefit of its customers, clients and
shareholders. Visit CTT's website: www.competitivetech.net.
Statements made about our future expectations are forward-looking statements and
subject to risks and uncertainties as described in our most recent Annual Report on
Form 10-K for the year ended July 31, 2009, filed with the SEC on October 27, 2009,
and other filings with the SEC, and are subject to change at any time. Our actual
results could differ materially from these forward-looking statements. We undertake
no obligation to update publicly any forward-looking statement.
Collaboration between Genencor and Goodyear results in breakthrough technology for tires made with renewable biomass
Collaboration between Genencor and Goodyear results in breakthrough technology for tires made with renewable biomass
The world’s first Goodyear concept tires made with BioIsoprenea technology arrive in Copenhagen in time for United Nations Climate Change Conference
The world’s first Goodyear concept demonstration tires made with BioIsopreneä technology made their debut in Copenhagen, Denmark, this week. BioIsopreneä is a breakthrough alternative to replace a petrochemically produced ingredient in the manufacture of synthetic rubber with renewable biomass. One Goodyear tire will be on display at a lounge in the common departure area at the Copenhagen International Airport throughout December 21, while the other tire will make appearances at several special events during the United Nations Climate Change Conference in Copenhagen (COP 15) through December. The tires made with BioIsopreneä are the result of a collaboration between Genencor, a division of Danisco, and Goodyear, one of the world’s largest tire companies and a leader in innovation.
“We are literally rolling out an important milestone in our collaboration with Goodyear on a breakthrough biochemical,” says Tom Knutzen, CEO of Danisco. “BioIsopreneä is an excellent example of Danisco’s leadership in industrial biotechnology through our Genencor division.”
“Goodyear’s first concept tire manufactured with BioIsopreneä shows the enormous progress we have made in using a bio-based alternative to the petroleum-derived raw material isoprene in our production process,” says Jesse Roeck, Director, Global Materials Science at Goodyear. “The development of BioIsopreneä could help us reduce industry impact on the environment by applying renewable raw materials in the supply chain and making Goodyear less dependent on oil-derived products.”
BioIsoprene product is derived from renewable raw materials, and represents a significant development within the biochemical and rubber industries. Aside from synthetic rubber for tire production, traditional isoprene is used for the production of a wide range of products, such as surgical gloves, golf balls and adhesives. Thus, the potential for BioIsoprene product is substantial.
Schedule of events for the world’s first Goodyear concept tires made from BioIsopreneä technology in Copenhagen, Denmark:
Through December 21 there will be a tire in the common departure area at The Copenhagen International AirportDecember 12-13 there will be a tire at the Bright Green exhibition in the Danisco boothDecember 17 a tire will be on display at the “Solutions of Industrial Biotechnology” Conference & Showcase, Confederation of Danish Industry (DI)A tire will also be on display in the Danisco headquarters’ reception area through December, please contact Danisco for an appointment (jennifer.hutchins@danisco.com)
Genencor and Goodyear first announced their research collaboration on the technology and integrated production system for BioIsoprene™ product in September 2008. The two organizations collaborate on designing an integrated production system for BioIsoprene™ product, and are on schedule to meet both technological and commercial milestones within the agreement. Commercial availability of the product is planned for 2013.
About Goodyear
Goodyear employs approximately 70,000 people and manufactures its products in more than 60 facilities in 25 countries around the world.
Goodyear’s innovations have set automotive standards for more than 100 years. Goodyear has been the pioneer of the innovative safety technology known as RunOnFlat, which allows a driver to continue on a journey with a punctured tire. Goodyear is the world’s leading manufacturer of RunOnFlat tires, with applications on various BMWs, the award winning Mini, Mercedes-Benz high performance cars, Opel and other brands. Additional Goodyear RunOnFlat fitments are on the horizon, as the company’s designers are working with multiple automobile manufacturers on more than 150 RunOnFlat projects.
The world’s first Goodyear concept tires made with BioIsoprenea technology arrive in Copenhagen in time for United Nations Climate Change Conference
The world’s first Goodyear concept demonstration tires made with BioIsopreneä technology made their debut in Copenhagen, Denmark, this week. BioIsopreneä is a breakthrough alternative to replace a petrochemically produced ingredient in the manufacture of synthetic rubber with renewable biomass. One Goodyear tire will be on display at a lounge in the common departure area at the Copenhagen International Airport throughout December 21, while the other tire will make appearances at several special events during the United Nations Climate Change Conference in Copenhagen (COP 15) through December. The tires made with BioIsopreneä are the result of a collaboration between Genencor, a division of Danisco, and Goodyear, one of the world’s largest tire companies and a leader in innovation.
“We are literally rolling out an important milestone in our collaboration with Goodyear on a breakthrough biochemical,” says Tom Knutzen, CEO of Danisco. “BioIsopreneä is an excellent example of Danisco’s leadership in industrial biotechnology through our Genencor division.”
“Goodyear’s first concept tire manufactured with BioIsopreneä shows the enormous progress we have made in using a bio-based alternative to the petroleum-derived raw material isoprene in our production process,” says Jesse Roeck, Director, Global Materials Science at Goodyear. “The development of BioIsopreneä could help us reduce industry impact on the environment by applying renewable raw materials in the supply chain and making Goodyear less dependent on oil-derived products.”
BioIsoprene product is derived from renewable raw materials, and represents a significant development within the biochemical and rubber industries. Aside from synthetic rubber for tire production, traditional isoprene is used for the production of a wide range of products, such as surgical gloves, golf balls and adhesives. Thus, the potential for BioIsoprene product is substantial.
Schedule of events for the world’s first Goodyear concept tires made from BioIsopreneä technology in Copenhagen, Denmark:
Through December 21 there will be a tire in the common departure area at The Copenhagen International AirportDecember 12-13 there will be a tire at the Bright Green exhibition in the Danisco boothDecember 17 a tire will be on display at the “Solutions of Industrial Biotechnology” Conference & Showcase, Confederation of Danish Industry (DI)A tire will also be on display in the Danisco headquarters’ reception area through December, please contact Danisco for an appointment (jennifer.hutchins@danisco.com)
Genencor and Goodyear first announced their research collaboration on the technology and integrated production system for BioIsoprene™ product in September 2008. The two organizations collaborate on designing an integrated production system for BioIsoprene™ product, and are on schedule to meet both technological and commercial milestones within the agreement. Commercial availability of the product is planned for 2013.
About Goodyear
Goodyear employs approximately 70,000 people and manufactures its products in more than 60 facilities in 25 countries around the world.
Goodyear’s innovations have set automotive standards for more than 100 years. Goodyear has been the pioneer of the innovative safety technology known as RunOnFlat, which allows a driver to continue on a journey with a punctured tire. Goodyear is the world’s leading manufacturer of RunOnFlat tires, with applications on various BMWs, the award winning Mini, Mercedes-Benz high performance cars, Opel and other brands. Additional Goodyear RunOnFlat fitments are on the horizon, as the company’s designers are working with multiple automobile manufacturers on more than 150 RunOnFlat projects.
Subscribe to:
Posts (Atom)